Product ID V0244Cas No. 175865-59-5Purity ≥98%

• Description
• Product Info
• Shipping and Storage
• Downloads
• References

Description

Valganciclovir is a mono-valyl ester prodrug of ganciclovir that is orally bioavailable and is well absorbed in the gastrointestinal system. Valganciclovir is an antiviral compound that, like ganciclovir, is an analog of 2’-deoxy-guanosine that is incorporated into DNA by viral DNA polymerase, preventing chain elongation. This compound is used to treat cytomegalovirus (CMV) in newborns and adults and may also exhibit benefit in the treatment of Kaposi sarcoma flares.

Product Info

Cas No.PurityFormulaFormula Wt.IUPAC NameAppearance

175865-59-5

≥98%

C14H22N6O5 • HCl

354.36

[2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl](2S)-2-amino-3-methylbutanoate;hydrochloride

White to off white powder

Shipping and Storage

Store TempShip Temp

Ambient

Ambient

Downloads

Info Sheet

V0244 Info Sheet PDF

References

Stronati M, Lombardi G, Garofoli F, et al. Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection. Curr Drug Metab. 2013 Feb;14(2):208-15. PMID: 22935067.

Iwasenko JM, Scott GM, Rawlinson WD, et al. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J Med Virol. 2009 Mar;81(3):507-10. PMID: 19152402.

Pantanowitz L, Früh K, Marconi S, et al. Pathology of rituximab-induced Kaposi sarcoma flare. BMC Clin Pathol. 2008 Jul 23;8:7. PMID: 18651955.

>>> 更多资讯详情请访问蚂蚁淘商城